LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Accueil・Liste d'Actions・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Fermé

SecteurSoins de santé

33.29 -3.2

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.52

Max

34.36

Chiffres clés
By Trading Economics
Revenu	-14M -81M
Ventes	75K 75K
BPA	-1.22
Marge bénéficiaire	-108,422.667
Employés	198
EBITDA	-7.8M -81M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+64.58% upside

Dividendes
By Dow Jones
Prochains Résultats	13 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	956M 2.6B
Ouverture précédente	36.49
Clôture précédente	33.29

Sentiment de l'Actualité

By Acuity

50%

166 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

18.91 / 20.63 Support & Résistance

Celldex Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 mai 2026, 23:58 UTC

Résultats

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mai 2026, 22:57 UTC

Résultats

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mai 2026, 23:52 UTC

Résultats

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mai 2026, 23:11 UTC

Résultats

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mai 2026, 23:06 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mai 2026, 23:05 UTC

Résultats

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mai 2026, 23:04 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mai 2026, 23:03 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mai 2026, 23:03 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mai 2026, 23:02 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mai 2026, 22:42 UTC

Résultats

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mai 2026, 22:33 UTC

Résultats

Acquisitions, Fusions, Rachats

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 22:32 UTC

Résultats

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mai 2026, 22:31 UTC

Résultats

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mai 2026, 22:31 UTC

Résultats

Macquarie: 68% of FY Income From International >MQG.AU

7 mai 2026, 22:30 UTC

Résultats

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mai 2026, 22:30 UTC

Résultats

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mai 2026, 22:29 UTC

Résultats

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mai 2026, 22:28 UTC

Résultats

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mai 2026, 22:28 UTC

Résultats

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mai 2026, 22:27 UTC

Résultats

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mai 2026, 22:27 UTC

Résultats

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mai 2026, 22:26 UTC

Résultats

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mai 2026, 22:25 UTC

Résultats

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparaison

Variation de prix

Celldex Therapeutics Inc prévision

Objectif de Prix

By TipRanks

64.58% hausse

Prévisions sur 12 Mois

Moyen 56.6 USD 64.58%

Haut 90 USD

Bas 34 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

18.91 / 20.63Support & Résistance

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

166 / 347Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.